Literature DB >> 12214321

The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs.

Abi Adebowale1, Jianpin Du, Zhonming Liang, James L Leslie, Natalie D Eddington.   

Abstract

OBJECTIVE: The purpose of this study was to determine the oral bioavailability and pharmacokinetics of a glucosamine (GL) and the disaccharides of chondroitin sulfate (CS) after single and multiple-dosing of a GL/CS combination (Cosamin, Cosequin).
METHODS: Male beagle dogs (n = 8, 12 kg) received the following treatments: (1) IV GL (500 mg)/CS (400 mg), (2) p.o. GL (1500 mg)/CS (1200 mg), (3) p.o. GL (2000 mg)/CS (1600 mg), (4) p.o. GL (1500 mg)/CS (1200 mg) QD for days 1-7 and p.o. GL (3000 mg)/CS (2400 mg) from days 8 to 14. Blood samples were collected over 24 h and glucosamine and the disaccharides of chondroitin sulfate were determined. Pharmacokinetic analysis was performed on glucosamine and total chondroitin sulfate disaccharides and parameters were compared across treatments using ANOVA with post hoc analysis. RESULT: After the IV administration, glucosamine declined rapidly in a bi-exponential fashion with a mean (+/- S.D.) elimination t(1/2) of 0.52 (0.25) h. GL absorption was relatively fast (C(max) = 8.95 microg/ml, and T(max) 1.5 h after 1500 mg dose) and the mean bioavailability of glucosamine after single dosing was approximately 12%. The extent of absorption of chondroitin sulfate as indicated by the mean C(max) (21.5 microg/ml) and mean AUC (187 microg/ml h) of total disaccharides after dosing (1600 mg) provides evidence that chondroitin sulfate is absorbed orally. The bioavailability of CS ranged from 4.8 to 5.0% after single dosing and 200-278% upon multiple dosing.
CONCLUSION: The results of this study show that both glucosamine and chondroitin sulfate (measured as total disaccharides) are bioavailable after oral dosing. In addition, the low molecular weight chondroitin sulfate used in this study displays significant accumulation upon multiple dosing. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12214321     DOI: 10.1002/bdd.315

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  20 in total

1.  Pharmacological effects of a C-phycocyanin-based multicomponent nutraceutical in an in-vitro canine chondrocyte model of osteoarthritis.

Authors:  Stephanie E Martinez; Yufei Chen; Emmanuel A Ho; Steven A Martinez; Neal M Davies
Journal:  Can J Vet Res       Date:  2015-07       Impact factor: 1.310

Review 2.  The use of glucosamine therapy in osteoarthritis.

Authors:  Djamila Zerkak; Maxime Dougados
Journal:  Curr Pain Headache Rep       Date:  2004-12

3.  Chondroprotective activity of N-acetylglucosamine in rabbits with experimental osteoarthritis.

Authors:  A R Shikhman; D Amiel; D D'Lima; S-B Hwang; C Hu; A Xu; S Hashimoto; K Kobayashi; T Sasho; M K Lotz
Journal:  Ann Rheum Dis       Date:  2005-01       Impact factor: 19.103

4.  Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness.

Authors:  B A Biggee; C M Blinn; T E McAlindon; M Nuite; J E Silbert
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

5.  Effects of [3H]glucosamine concentration on [3H]chondroitin sulphate formation by cultured chondrocytes.

Authors:  Paula J Mroz; Jeremiah E Silbert
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

Review 6.  The use of glucosamine therapy in osteoarthritis.

Authors:  Djamila Zerkak; Maxime Dougados
Journal:  Curr Rheumatol Rep       Date:  2004-02       Impact factor: 4.592

7.  Dietary glucosamine under question.

Authors:  Jeremiah E Silbert
Journal:  Glycobiology       Date:  2009-03-02       Impact factor: 4.313

8.  Disc size markedly influences concentration profiles of intravenously administered solutes in the intervertebral disc: a computational study on glucosamine as a model solute.

Authors:  S Motaghinasab; A Shirazi-Adl; M Parnianpour; J P G Urban
Journal:  Eur Spine J       Date:  2013-12-29       Impact factor: 3.134

9.  Metabolomic analyses of blood plasma after oral administration of D-glucosamine hydrochloride to dogs.

Authors:  Tomohiro Osaki; Kazuo Azuma; Seiji Kurozumi; Yoshimori Takamori; Takeshi Tsuka; Tomohiro Imagawa; Yoshiharu Okamoto; Saburo Minami
Journal:  Mar Drugs       Date:  2012-08-22       Impact factor: 6.085

10.  Impact of Glucosamine Supplementation on Gut Health.

Authors:  Jessica M Moon; Peter Finnegan; Richard A Stecker; Hanna Lee; Kayla M Ratliff; Ralf Jäger; Martin Purpura; Carolyn M Slupsky; Maria L Marco; Craig J Wissent; Jason Theodosakis; Chad M Kerksick
Journal:  Nutrients       Date:  2021-06-24       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.